New product in development diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Zygel™ in pivotal Phase 3 trial for Fragile X syndrome and has completed Phase 2 proof-of-concept study in 22q11.2 deletion syndrome PLYMOUTH MEETING, Pa. , Oct. 11, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony")... Read More

DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer (the “Offer”) by Harmony Biosciences Holdings, Inc. (“Harmony”) and its wholly owned... Read More

DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending tender offer by Harmony Biosciences Holdings, Inc. (“Harmony”). Fellow Zynerba Pharmaceuticals Stockholders, We urge you to promptly... Read More

PLYMOUTH MEETING , Pa. , Sept. 27, 2023 /PRNewswire/ -- In connection with the previously announced merger agreement, Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), today announced that Xylophone Acquisition Corp., a wholly owned subsidiary of Harmony, has extended the expiration of its tender offer to acquire all of the outstanding shares of common stock of Zynerba Pharmaceuticals, Inc. ("Zynerba") (Nasdaq:... Read More

DEVON, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, announces an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 25 th International Research Symposium, being held virtually September 14-15, 2023. Helen (Honey) Heussler, MBBS... Read More

PLYMOUTH MEETING, Pa. and DEVON, Pa. , Aug. 14, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. ("Zynerba") (Nasdaq: ZYNE), a leader in innovative pharmaceutically-produced... Read More

DEVON, Pa., July 25, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the new date for the adjourned 2023 Annual Meeting of Stockholders (“Annual Meeting”) is August 11, 2023 at 9:00 a.m. EDT in order to provide stockholders additional time to... Read More

Annual Meeting Reconvened and Adjourned Without Conducting Business Meeting to Reconvene on July 27, 2023 at 9:00 am EDT DEVON, Pa., June 28, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the adjourned 2023 Annual Meeting of Stockholders... Read More

DEVON, Pa., June 20, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference being held June 26, 2023. Investors... Read More

Meeting adjourned with respect to Proposal 2, Reverse Stock Split; Company encourages additional stockholders of record to vote before reconvened meeting on June 28, 2023 All other proposals approved DEVON, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) (the “Company”), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric... Read More

DEVON, Pa., May 23, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced an oral podium presentation and poster presentations at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2023), being held May 30 – June 2, 2023, in Miami, Fla. Copies of... Read More

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 $44.4 million in cash and cash equivalents at March 31, 2023; Cash runway to mid-year 2024 Proposal for a reverse stock split is on the agenda for June 13, 2023 annual meeting of stockholders to satisfy the minimum bid price requirement for continued listing on the... Read More

Zygel continued to be well-tolerated with long-term administration and maintained clinically meaningful improvements in children and adolescents with Fragile X syndrome Zygel achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment in INSPIRE, a Phase 2 trial with Zygel in children and adolescents... Read More

DEVON, Pa., April 05, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of two posters at the 55 th Gatlinburg Conference, being held April 10-13, 2023, in Kansas City, Mo. Copies of the posters will be made available on the Zynerba corporate... Read More

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 European Commission granted orphan drug designation for cannabidiol, the active ingredient in Zygel, in 22q11.2 deletion syndrome $50.6 million in cash and cash equivalents at December 31, 2022; Cash runway to mid-year 2024 DEVON, Pa., March 28, 2023 (GLOBE NEWSWIRE)... Read More

DEVON, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today issued a statement confirming that it does not hold cash deposits or securities at Silicon Valley Bank. About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in innovative... Read More

DEVON, Pa, March 07, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the virtual Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, at 4:40... Read More

DEVON, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at Cowen’s 43 rd Annual Health Care Conference on Wednesday, March 8, 2023, at 2:50 p.m. ET, and... Read More

Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the pathogenesis of Fragile X syndrome (FXS) Cannabidiol may help restore the function of the ECS in FXS patients according to review of data Consistent with the proposed mechanisms of action of cannabidiol in FXS, Zygel™ showed a significant reduction in behavioral symptoms, in patients... Read More

RECONNECT initial screening visits are being adversely impacted by environmental factors, such as the “Tripledemic” (high rates of RSV, influenza and COVID-19); topline results now expected first half of 2024 Cash runway extended to mid-year 2024 due to prioritization of resources on the completion of the RECONNECT trial DEVON, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader... Read More

Zygel™ achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment DEVON, Pa., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, presented positive... Read More

DEVON, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of a poster at the 61 st Annual Meeting of the American College of Neuropsychopharmacology, being held December 4-7, 2022 in Phoenix, Ariz. A copy of the poster will be made... Read More

Study finds patients with Fragile X who have a highly methylated FMR1 gene that were treated with Zygel showed a significant reduction in behavioral symptoms compared to those treated with placebo Topline results from follow-on RECONNECT confirmatory pivotal Phase 3 trial of Zygel in patients with a completely methylated FMR1 gene expected in second half 2023 DEVON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Zynerba... Read More

DEVON, Pa., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the European Commission (EC) has granted orphan drug designation to cannabidiol, the active ingredient in its transdermal gel, Zygel™, for the treatment of 22q11.2 deletion syndrome (22q).... Read More

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 $55.9 million in cash and cash equivalents at September 30, 2022; Cash runway into first quarter 2024 DEVON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,458,109, titled “Treatment of 22q11.2 Deletion Syndrome With Cannabidiol,” which includes claims directed to methods of treating one or more behavioral symptoms of 22q11.2... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, presented a poster at the 2022 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit being held October 17-18, 2022, in Washington, D.C. A copy of the poster is available on the Zynerba corporate website at... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of a poster at the 2022 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit being held October 17-18, 2022 in Washington, D.C. A copy of the poster will be made available on... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,458,110, titled “Treatment of Fragile X Syndrome With Cannabidiol,” which includes claims directed to methods of treating Fragile X syndrome with cannabidiol. This new... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Stephen O’Quinn, Pharm.D., Vice President, Medical Affairs, Zynerba Pharmaceuticals, will participate in a panel discussion at the 2022 Cantor Neurology & Psychiatry Conference being held October 6-7, 2022 in San Francisco, Calif. In... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:00 p.m. ET, and host investor meetings. The... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, announces an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24 th International Research Symposium, being held in Oslo, Norway, September 8-10, 2022. Helen (Honey) Heussler, MBBS FRACP MRCPCH, DM, Associate Professor,... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present in-person at the H.C. Wainwright 24 th Annual Global Investment Conference on Tuesday, September 13, 2022, at 2:00 p.m. ET, and host investor... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the acceptance of an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24 th International Research Symposium, which will be held in Oslo, Norway, September 8-10, 2022. A copy of the presentation slides will be... Read More

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 Announced positive topline results from Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q) Company focusing resources on orphan neuropsychiatric disorders, FXS and 22q $62.5 million in cash and cash equivalents at June 30, 2022; Cash runway... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present an overview and update of the Company at the Canaccord Genuity 42 nd Annual Growth Conference on Wednesday, August 10, 2022 at 9:00 a.m. ET at... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced it has entered into an equity purchase agreement for up to $20 million with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor. Under the terms of the agreement, Zynerba will have the right in its sole discretion,... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced two poster presentations at the 18 th NFXF International Fragile X Conference, being held July 14-17, 2022, in San Diego, Calif. In addition, Zynerba management will present a company presentation during the conference’s Keynote... Read More

The INSPIRE trial achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments Safety data reinforce excellent tolerability profile of Zygel Company will focus resources on FXS and 22q development Cash runway extended through the end of 2023 / early 2024 Zynerba to host conference call and webcast tomorrow, June 22, 2022 at 9:00 a.m. ET Zynerba Pharmaceuticals , Inc... Read More

Poster presentation highlights design enhancements incorporated into pivotal RECONNECT trial Oral presentation demonstrates long-term safety and potential effectiveness of Zygel in children and adolescents with Fragile X syndrome Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting... Read More

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced an oral podium presentation and a poster presentation at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2022), being held May 31 – June 3, 2022, in Scottsdale, Ariz. A copy of the presentations will be... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present virtually at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022. A webcast of the presentation will be... Read More

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 Topline results from Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q) expected mid-year 2022 $69.7 million in cash and cash equivalents at March 31, 2022; Cash runway into second-half 2023 Zynerba Pharmaceuticals , Inc . (Nasdaq: ZYNE),... Read More

Data support the long-term safety and effectiveness of Zygel Greatest improvements seen in those with complete methylation of their FMR1 gene Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting an oral podium presentation at the International Society for Autism Research Annual... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced an oral podium presentation at the International Society for Autism Research Annual Meeting (INSAR 2022), being held both in-person and virtually May 11-14, 2022, from Austin, TX. A copy of the presentation will be made available... Read More

Z ynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting, held April 28-30, 2022, in New Orleans, La., and virtually. A copy of the poster is available on the Zynerba corporate website at... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting, being held April 28-30, 2022, in New Orleans, La., and virtually. A copy of the poster will be made available on the Zynerba... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of Zynerba, will present a company overview during the 21 st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022, at 12:45 p.m. ET. Investors interested in arranging... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Stephen O’Quinn, Vice President, Medical Affairs, Zynerba Pharmaceuticals, will participate in a panel discussion at the 2022 Cantor Rare Orphan Disease Summit taking place virtually March 29-30, 2022. Panel Details Title:... Read More

European Commission granted orphan drug designation for Zygel™ in Fragile X syndrome (FXS) Continued enrollment in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with FXS; topline results expected second-half 2023 Completed enrollment in Phase 2 trial of Zygel in patients with 22q11.2 deletion syndrome (22q); topline results expected mid-year 2022 $67.8 million in cash and cash equivalents at December... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the European Commission (EC) has granted orphan drug designation to cannabidiol, the active ingredient in its transdermal gel, Zygel™, for the treatment of Fragile X syndrome (FXS). “Orphan drug designation by the EC is... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the appointment of Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as Chief Legal Officer and Corporate Secretary. He will assume the duties of Suzanne... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will virtually present a company overview during the 11 th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 a.m. ET.... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present during the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022. A webcast of the presentation will be... Read More

Company plans to focus development of Zygel™ in FXS, ASD and 22q Company plans to initiate Phase 3 trial with Zygel in ASD in the second half of 2022 Zynerba to hold conference call tomorrow, January 5, 2022 at 9:00 a.m. ET Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today provided program... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced presentation details for The BRAIN Foundation Synchrony 2021 Symposium, being held virtually December 11-12, 2021. The presentation can be accessed by registering for free at https://synchronysymposium.com/ . A copy of the... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the European Patent Office has issued Patent No. 3687513, titled “ Treatment of Fragile X Syndrome and Autism with Cannabidiol ,” which includes claims directed to methods of treating one or more behavioral symptoms of... Read More

Initiated RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X Syndrome (FXS); topline results expected second-half 2023 Cash runway well into the first half of 2024; $75.6 million at September 30, 2021 Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced oral and poster presentations at the Society for Developmental & Behavioral Pediatrics Annual Meeting, being held virtually October 21-25, 2021, and the 68 th American Academy of Child & Adolescent Psychiatry Annual Meeting,... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit being held virtually October 18-19, 2021. A copy of the poster titled, “ RECONNECT... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 American Academy of Pediatrics (AAP) National Conference & Exhibition, which will be held virtually from October 8-11, 2021. A copy of the poster titled, “ Longer Term Tolerability and... Read More

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will participate in a fireside chat during the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 11:20 a.m. ET. Investors... Read More

Trial will evaluate the efficacy and safety of Zygel in children and adolescents with Fragile X Syndrome Topline results expected in second half of 2023 Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announces the initiation of a pivotal, multinational randomized, double-blind,... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today presented data from the Phase 2 BRIGHT trial describing tolerability and efficacy of Zygel (cannabidiol formulated in a transdermal gel [ZYN002]) in children and adolescents with autism spectrum disorder (ASD) over a longer term, 38-week... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the publication of results from the Company’s open-label Phase 2 BELIEVE (Open La b el Study to Assess the Safety and E fficacy of Zygel™ (ZYN002) Administered as a Transderma l Gel to Ch i ldren and Adol e scents with De v... Read More

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will participate in a fireside chat during the H.C. Wainwright 23 rd Annual Global Investment Conference being held virtually September 13-15, 2021. Investors... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and oral presentation details of two sets of data at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021, which will be held virtually from September 9-10, 2021. A copy of the presentation... Read More

On track to initiate RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, in the third quarter of 2021 Positive feedback from FDA clarifies potential path forward in ASD Cash runway well into the first half of 2024; $85.8 million at June 30, 2021 Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare... Read More

DEVON, Pa., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Company management will participate in a fireside chat during the Canaccord Genuity 41 st Annual Growth Conference being held virtually on Wednesday, August 11, 2021 at 1:30 p.m.... Read More

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Ladenburg Thalmann Virtual Healthcare Conference on Wednesday, July 14, 2021 at 12:00 p.m. ET. Investors interested in... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster today at SLEEP 2021, the 35 th Annual Meeting of the Associated Professional Sleep Societies, LLC. A copy of the poster is available on the Zynerba corporate website at http://zynerba.com/publications/ . The poster titled “... Read More

46.4% of shares voted, quorum not established to hold annual meeting Meeting scheduled to reconvene June 29, 2021 at 9:00 AM EDT Company strongly encourages stockholders holding unvoted proxies to cast their votes Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that it has... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of a poster at SLEEP 2021, the 35 th Annual Meeting of the Associated Professional Sleep Societies, LLC, which will be held virtually from June 10-13, 2021. A copy of the poster will be... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster today from 10:00 a.m. – 11:00 a.m. ET in poster session II at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. A copy of the poster is available on the Zynerba corporate website at... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of a poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. The ASCP annual meeting is being held virtually June 1-4, 2021. A copy of the poster will be... Read More

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will present a company overview during the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 4:30 p.m. ET. Investors interested in arranging a... Read More

DEVON, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE IN RE ZYNERBA PHARMACEUTICALS, INC. DERIVATIVE LITIGATION Lead Case No. 1:20-cv-00557-CFC NOTICE TO CURRENT ZYNERBA SHAREHOLDERS OF PROPOSED SETTLEMENT AND DISMISSAL WITH PREJUDICE OF DERIVATIVE ACTION TO: ALL OWNERS OF ZYNERBA PHARMACEUTICALS, INC. (“ZYNERBA” OR THE “COMPANY”) STOCK (TICKER SYMBOL: ZYNE). PLEASE... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced an oral podium presentation and a poster presentation at the Virtual ISPOR 2021 conference taking place May 17-20, 2021. Both the podium and poster presentations are available on the Virtual ISPOR 2021 program gallery and on the... Read More

RECONNECT, a confirmatory pivotal trial of Zygel™ in patients with FXS, expected to be initiated in the third quarter of 2021 Cash runway well into first half 2024; $93.1 million at March 31, 2021 Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the first... Read More

Confirmatory pivotal trial expected to be initiated in the third quarter of 2021 Zynerba to hold conference call today, May 5, 2021 at 5:30 pm ET Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the Company has received guidance from the U.S. Food and Drug Administration (FDA)... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting. Both posters will be made available on the Zynerba corporate website at the time of their presentations at http://zynerba.com/publications/ . The... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting. The SOBP annual meeting is being held virtually from April 29 through May 1, 2021. A copy of the posters... Read More

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of Zynerba, will present a company overview during the 20 th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 1:30 p.m. ET. Investors interested in arranging a... Read More

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the fourth quarter and full year ended December 31, 2020, and provided an overview of recent operational highlights and a pipeline update. “We expect to make significant progress in 2021 on all four... Read More

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Company management will participate in the 33 rd Annual ROTH Conference, which will be held virtually on March 15-17, 2021. Investors interested in arranging a virtual meeting with the Company’s management on Wednesday, March... Read More